Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$12.2MCash on Hand
14.2mo Cash Runway
Follow ASBP by emailGet an email when ASBP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ASBP, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Oct 20, 2026 ·
Deal Aspire-Lakewood amended its 8-K to add a Management Services Agreement with Lakewood Capital, LLC, effective August 6, 2026, for five years. Lakewood gets a $500,000 closing fee, an annual fee of 5% of Adjusted EBITDA capped at $1,000,000, and 15% of Dura Control Systems equity, estimated at about $4,500,000. Form 8-K/A · SEC filing · Press release
Sep 29, 2026 ·
Leadership Aspire-Lakewood dismissed auditor Turner Stone & Company on September 24, 2026, and engaged CBIZ CPAs P.C. as its new independent registered public accounting firm for fiscal 2026. Form 8-K · SEC filing
Sep 9, 2026 ·
Listing Aspire-Lakewood Holdings, formerly Aspire Biopharma Holdings, changed its name effective September 8, 2026 without stockholder approval, keeping the ASPB Nasdaq symbol and CUSIP unchanged. Separately, the board raised its share repurchase authorization to $10 million. Form 8-K · SEC filing · Press release
Sep 8, 2026 ·
Aspire Biopharma Holdings, Inc. changed its corporate name to Aspire-Lakewood Holdings, Inc., effective upon a Delaware Certificate of Amendment, following its acquisition of Dura Control Systems Corp. The Nasdaq ticker ASBP is unchanged, though the filing also cites ASPB, and no stockholder action is required. Form 8-K · SEC filing · Press release
Aug 19, 2026 ·
The company intends to distribute an investor presentation on August 19, 2026, furnished as Exhibit 99.1. The filing text itself reports no results, financing or other substantive news. Form 8-K · SEC filing · Press release
Aug 13, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Aug 10, 2026 ·
Deal Aspire closed its purchase of Dura Driver Control Systems, with the closing triggered by its payment of the $30.0 million Closing Purchase Price, funded in part by a $22.5 million senior secured revolving facility. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Oct 2025 · N/A · Results Expected · A Replicate Crossover Trial on Nutritional Supplementation in Association Football (Soccer) Registry primary completion date, not a results date
Mar 2018 · Phase 4 · Results Expected · A Pilot Investigation Detecting Cryoablation Scar by 3D Late Gadolinium Enhancement Registry primary completion date, not a results date
Jun 2015 · N/A · Results Expected · Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study Registry primary completion date, not a results date
Sep 2013 · Phase 4 · Results Expected · Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging Registry primary completion date, not a results date
Jan 2012 · N/A · Results Expected · Efficiency and Outcomes of Stress-Only Anger and D-SPECT Stress-Only SPECT MPI Registry primary completion date, not a results date
Feb 2009 · N/A · Results Expected · Tongue Advancement for Obstructive Sleep Apnea Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ASBP holds $12.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $2.6M/quarter from operations,
an estimated runway of 14.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:8 · Low
Cash runway 14 months +18
Raised after last reported balance sheet (Aug 2026) -10
Share count 1,402,557 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ASBP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASBP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.